Your browser is no longer supported. Please, upgrade your browser.
NVAX Novavax, Inc. daily Stock Chart
NVAX [NASD]
Novavax, Inc.
Index- P/E- EPS (ttm)-4.14 Insider Own0.20% Shs Outstand58.69M Perf Week19.00%
Market Cap10.11B Forward P/E9.00 EPS next Y18.92 Insider Trans-19.19% Shs Float54.38M Perf Month76.83%
Income-115.30M PEG- EPS next Q-0.41 Inst Own29.00% Short Float14.95% Perf Quarter809.18%
Sales18.10M P/S558.66 EPS this Y44.90% Inst Trans24.48% Short Ratio0.82 Perf Half Y2598.73%
Book/sh-0.54 P/B- EPS next Y146.19% ROA-53.90% Target Price135.00 Perf Year3796.80%
Cash/sh4.00 P/C42.59 EPS next 5Y0.00% ROE78.80% 52W Range3.54 - 189.40 Perf YTD4178.64%
Dividend- P/FCF- EPS past 5Y5.60% ROI- 52W High-10.09% Beta1.72
Dividend %- Quick Ratio13.40 Sales past 5Y-9.50% Gross Margin- 52W Low4710.45% ATR14.18
Employees165 Current Ratio13.40 Sales Q/Q-15.00% Oper. Margin- RSI (14)75.87 Volatility9.74% 10.59%
OptionableYes Debt/Eq- EPS Q/Q72.50% Profit Margin- Rel Volume0.65 Prev Close167.50
ShortableYes LT Debt/Eq- EarningsMay 11 AMC Payout- Avg Volume9.97M Price170.29
Recom2.50 SMA2023.54% SMA5082.14% SMA200429.08% Volume6,495,921 Change1.67%
Aug-06-20Reiterated H.C. Wainwright Buy $132 → $290
Aug-05-20Upgrade JP Morgan Neutral → Overweight $275
Aug-05-20Downgrade Ladenburg Thalmann Neutral → Sell $105
Jul-16-20Reiterated H.C. Wainwright Buy $101 → $132
Jul-08-20Downgrade Ladenburg Thalmann Buy → Neutral $50 → $105
Jun-29-20Reiterated H.C. Wainwright Buy $50 → $101
Jun-29-20Reiterated B. Riley FBR Buy $74 → $106
Jun-05-20Upgrade JP Morgan Underweight → Neutral $46
May-28-20Reiterated B. Riley FBR Buy $53 → $61
May-12-20Reiterated H.C. Wainwright Buy $33 → $50
Apr-30-20Reiterated H.C. Wainwright Buy $24 → $33
Nov-27-19Resumed B. Riley FBR Buy $12
Aug-14-19Reiterated H.C. Wainwright Buy $10 → $17
Feb-28-19Downgrade Piper Jaffray Overweight → Underweight $4.50 → $0.25
Dec-18-18Initiated Ladenburg Thalmann Buy $3
Dec-11-18Initiated Oppenheimer Outperform $4
Nov-26-18Upgrade Piper Jaffray Neutral → Overweight
Sep-21-18Upgrade JP Morgan Underweight → Overweight
Mar-29-18Upgrade Seaport Global Securities Neutral → Buy $5
Mar-19-18Downgrade JP Morgan Neutral → Underweight
Aug-07-20 03:00PM  
11:58AM  
11:30AM  
11:02AM  
08:02AM  
08:00AM  
07:34AM  
06:00AM  
05:26AM  
Aug-06-20 04:49PM  
02:04PM  
09:44AM  
06:45AM  
03:18AM  
Aug-05-20 09:17PM  
06:58PM  
04:29PM  
04:28PM  
04:14PM  
03:26PM  
02:24PM  
01:35PM  
12:55PM  
12:11PM  
12:03PM  
11:59AM  
10:04AM  
10:03AM  
10:00AM  
09:59AM  
08:53AM  
08:39AM  
08:22AM  
07:35AM  
05:13AM  
Aug-04-20 11:55PM  
09:52PM  
09:35PM  
05:59PM  
05:23PM  
05:19PM  
04:05PM  
Aug-02-20 09:07AM  
08:14AM  
Aug-01-20 06:49AM  
06:33AM  
Jul-31-20 11:47AM  
09:25AM  
Jul-30-20 05:45PM  
Jul-29-20 02:32PM  
12:33PM  
Jul-28-20 02:36PM  
11:28AM  
Jul-27-20 10:22PM  
02:50PM  
11:48AM  
11:12AM  
Jul-26-20 02:33PM  
09:34AM  
08:00AM  
Jul-25-20 02:06AM  
Jul-24-20 07:01PM  
03:28PM  
12:16PM  
10:36AM  
09:10AM  
07:15AM  
Jul-23-20 04:04PM  
07:55AM  
Jul-22-20 03:38PM  
08:05AM  
07:10AM  
Jul-21-20 06:18PM  
05:45PM  
03:16PM  
08:51AM  
08:24AM  
08:07AM  
Jul-20-20 07:12PM  
05:23PM  
04:05PM  
Jul-19-20 02:33PM  
10:23AM  
09:00AM  
07:04AM  
06:13AM  
Jul-18-20 07:03AM  
Jul-17-20 04:40PM  
04:23PM  
01:01PM  
12:35PM  
11:55AM  
11:50AM  
09:57AM  
08:46AM  
Jul-16-20 04:50PM  
04:16PM  
Jul-15-20 05:45PM  
01:15PM  
08:32AM  
Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate that in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase III clinical trial for treating seasonal influenza in older adults. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, and the immune systems attack against microorganisms, as well as to allow immunization with much lower doses of antigen. The company is also developing RSV F vaccine for older adults (60 years and older) that is in Phase II clinical trial, as well as for healthy children between six months to five years of age that is in Phase I clinical trial. In addition, it develops nanoparticle vaccine candidates for clinic testing against ebola virus that is in Phase I clinical trial; and combination respiratory vaccine to protect against influenza and RSV. Further, the company is developing COVID-19 vaccine for coronavirus that causes pneumonia-like symptoms, which is in preclinical stage. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Glenn Gregory MPresident, R&DJun 18Option Exercise42.2016,749706,80818,588Jun 22 05:29 PM
Glenn Gregory MPresident, R&DJun 18Sale59.5316,749997,1031,839Jun 22 05:29 PM
YOUNG JAMES FDirectorJun 03Buy48.831,50073,2451,500Jun 05 05:04 PM
Herrmann John A IIISVP, General CounselMay 18Option Exercise26.1912,961339,4487,774May 20 04:35 PM
Herrmann John A IIISVP, General CounselMay 18Sale49.4412,961640,792275May 20 04:35 PM
Glenn Gregory MPresident, R&DJan 31Buy3.861,2504,8251,373Feb 04 05:11 PM
MCMANUS MICHAEL A JRDirectorNov 18Sale3.823,92915,0159,951Nov 20 04:17 PM
Herrmann John A IIISVP, General CounselSep 17Sale7.073,64325,7570Sep 18 04:14 PM
Glenn Gregory MPresident, R&DSep 13Sale6.189,62059,476123Sep 16 04:18 PM
Trizzino JohnSVP, CBO and CFOSep 11Sale5.725,57831,9114,800Sep 12 04:29 PM